Grants for For Profit Organizations Other Than Small Businesses

This grant from Sanofi's Rare Blood Disorders Medical Affairs department focuses on medical education programs addressing Immune Thrombocytopenia (ITP). The grant aims to support independent medical education (IME) activities that recap highlights from EHA 2024 and ISTH 2024 conferences on ITP, emphasizing enduring programs, accredited or non-accredited IME activities, and digital or omnichannel formats. Proposals should address existing healthcare gaps in the treatment and management of ITP, improving clinician knowledge and patient outcomes. The maximum grant request is $150,000, with a focus on comprehensive interventions that address knowledge and performance gaps in ITP treatment. Proposals should cover target audience generation, learning objectives, educational methods, faculty recruitment, program evaluation, and budget planning.

Ladies/Gentlemen: The United States Agency for International Development (USAID) is seeking applications for a Leader with Associate (LWA) cooperative agreement from qualified entities to implement the Civic DEFENDERS program. Eligibility for this award is not restricted. USAID intends to make an award to the applicant who best meets the objectives of this funding opportunity based on the merit review criteria described in this NOFO subject to a risk assessment. Eligible parties interested in submitting an application are encouraged to read this NOFO thoroughly to understand the type of program sought, application submission requirements, and selection process. To be eligible for award, the applicant must provide all information as required in this NOFO and meet eligibility standards in Section C of this NOFO. This funding opportunity is posted on www.grants.gov, and may be amended. It is the responsibility of the applicant to regularly check the website to ensure they have the latest information pertaining to this notice of funding opportunity and to ensure that the NOFO has been received from the internet in its entirety. USAID bears no responsibility for data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the NOFO, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at [email protected] for technical assistance. USAID may not award to an applicant unless the applicant has complied with all applicable Unique Entity Identifier and System for Award Management (SAM) requirements detailed in Section D.6.g. The registration process may take many weeks to complete. Therefore, applicants are encouraged to begin registration early in the process. Please send any questions to the point(s) of contact identified in Section G. The deadline for questions is shown above. Responses to questions received prior to the deadline will be furnished to all potential applicants through an amendment to this notice posted to www.grants.gov. Issuance of this notice of funding opportunity does not constitute an award commitment on the part of the Government nor does it commit the Government to pay for any costs incurred in preparation or submission of comments/suggestions or an application. Applications are submitted at the risk of the applicant. All preparation and submission costs are at the applicants expense. Thank you for your interest in USAID programs. Sincerely, Mir Ershadullah Agreement Officer

This program provides funding to organizations and local governments in Texas to develop and implement strategies that reduce pollution from diffuse sources, helping to protect and restore water quality in various watersheds.

There are over 3,100 local jails and 80 Indian country jails in the United States with a combined population on any given day of over 660,000 people. While these facilities vary drastically in size and age, the leaders of these facilities have more in common than not. Large or small, rural, or urban, the vast majority face the same challenges: staffing, succession planning, training, culture, resource shortages, data analysis, health care, substance abuse disorders, mental illness, facility design and operations, and early identification of trends and emerging issues within their populations, to name a few. And while there are commonalities among the many, the responsibility to the public for the life, health, and safety of the people in their custody and their employees while administering a constitutionally run jail is considerable and common to all.The Institute for Jail Administration (IJA) provides training to personnel in positions of leadership within local or tribal organizations responsible for operating a jail or that have a nexus to jail operations. The IJA assists them as leaders within their organizations and equips them to manage essential aspects of administering a jail and prepares them for positions of greater responsibility.

The FY24 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. If successful, the studies will enable progress toward addressing one or more of the FY24 PCRP Overarching Challenges. It is expected that any resources, tools, or computational processes generated by this award will be openly shared with the prostate cancer research and patient community. This mechanism is intended to fund research built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer: Computational biology Bioinformatics Artificial intelligence and machine learning Epidemiology Analysis of omics data Medical imaging Digital pathology Analysis of other clinically annotated datasetsApplications may combine diverse data types for integrative analysis to increase knowledge about prostate cancer with respect to the FY24 PCRP Overarching Challenges. Applications that propose to develop resources or tools that allow research, clinical care, and patient community access to standardized and harmonized datasets for real-time clinical care applications are of particular interest; however, this award must not be used to support the development of new datasets. Studies utilizing data derived from large patient studies that include long-term health records or repositories with well-annotated and high-quality biospecimens are encouraged.Key Features: Research Approach: Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large datasets with the intent of advancing prostate cancer research and patient care relative to the FY24 PCRP Overarching Challenges. Inclusion of preliminary data to support the scientific rationale and feasibility of research approaches is strongly encouraged, but not required. Any preliminary data provided should be from the laboratory of the Principal Investigator(s) (PI[s]) or member(s) of the collaborating team. Applicants are encouraged to include plans for rigorous validation, benchmarking, comparisons, and/or evaluations to assess the quality or utility of the tools and/or approaches that will be used or developed under this award. Any datasets used in the study design must be from established, retrospective databases and be sufficient in size to provide appropriate analytical and statistical power. Prospective recruitment of human subjects and/or clinical trials is not allowed under this funding opportunity. Applicants are expected to provide documentation demonstrating access to the appropriate datasets and/or patient samples in numbers sufficient to achieve robust results. Impact: Applications are required to clearly communicate how the proposed quantitative and/or analytical approaches, processes, and/or systems will address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short- and long-term, should be clearly described, including how the anticipated outcomes or products are distinct from existing research efforts in this area and/or how they will significantly outperform current approaches in this area. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Data and Resource Sharing Plan: It is expected that any resources, tools, and computational processes that are developed under this award will be openly shared with the prostate cancer research and patient community. Plans must be provided for how additional data generated by future studies will be incorporated to further inform and refine the data science tools, processes, and/or methods generated and/or used in this study. Refer to the CDMRPs Policy on Data Resource Sharing located on the Electronic Biomedical Research Application Portal (eBRAP) Funding Opportunities Forms web page https://ebrap.org/eBRAP/public/Program.htm for more information about the CDMRPs expectations for making data and research resources publicly available.Partnering PI Option: The FY24 PCRP Data Science Award encourages applications that include meaningful and productive collaborations between investigators. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application; collaborations between data scientists and clinicians are highly encouraged. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project, including the Project Narrative, Statement of Work (SOW) and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organization. Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/ nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Data Science Award should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $11.2M to fund approximately seven Data Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding initiative provides financial support to Texas-based public and private entities for semiconductor manufacturing and design projects that boost local economies and foster innovation in the industry.

Please see the full FOA in EERE Exchange. The research and development (R) activities to be funded under this FOA will support the government-wide approach to the climate crisis by driving the innovation that can lead to the deployment of clean energy technologies, which are critical for climate protection. Specifically, this FOA will fund innovative solar photovoltaics (PV) R that reduces the cost of PV modules, reduces carbon and energy intensity of PV manufacturing processes, and optimizes PV technology for new, specialized markets. SETOs PVRD program works to accelerate the deployment of solar energy technologies by funding innovative R in PV cell and module technologies, balance-of-system components, reliability tracing and tracking, metrology, and other key research questions in PV. To accelerate toward these deployment targets and augment SETOs ongoing PV research portfolio,12 this FOA will fund R on innovative cell- and minimodule-level technologies focused on three major goals: Enable cost reduction on an LCOE basis through development of durable, high-efficiency cell and module PV technology Identify pathways to reduce the carbon intensity and energy intensity of industrial processes required to fabricate PV cells and modules Increase technical viability of PV cells and modules tailored for emerging integrated PV sectors, such as building-integrated PV (BIPV) and vehicle-integrated PV. This FOA will fund innovative R projects that aim to advance the state of the art in various cell and module technologies to accomplish these goals of cost reduction, lower carbon intensity, and viability of dual-use markets. This FOA is separated into two topic areas: Photovoltaic Advances in Cell Efficiency, Reliability, and Supply Chain (PACERS): Applications in four PV supply chain, cell, and module technology spaces are of particular interest: low-carbon synthesis of metallurgical-grade silicon (MGS, here defined as silicon that is 98% pure as defined by the 5/5/3 standard)13 production, crystalline silicon (c-Si) PV, III-V PV, and organic PV (OPV). However, proposals for any industrial process, cell, or minimodule-level research that enables the goals of this FOA will be considered, excluding areas specified as not of interest in Section I.C., such as perovskite technology, which is addressed in other funding programs, and CdTe technology, which is addressed in Topic Area 2. Building Academic Capabilities in Cadmium Telluride: Applications describing advanced R projects requiring the procurement or upgrade of CdTe equipment are of interest. Proposals should detail work that will enhance fabrication, characterization, or analytical capabilities while also benefiting the larger CdTe PV research community.

This initiative supports local businesses and organizations dedicated to fostering economic growth in communities around Corning business locations. It focuses on empowering and supporting economic activities that align with Corning's values and objectives. Applications are reviewed continuously throughout the year to ensure timely support for impactful projects.

This funding opportunity provides financial support to small utility companies and public utilities in Oklahoma for improving their electricity service resiliency through various enhancements like weatherization and advanced technologies.

The "DoD Peer Reviewed Cancer, Idea Award" is a grant aimed at supporting innovative and high-risk basic cancer research that introduces new concepts or challenges existing paradigms, with the goal of advancing knowledge in cancer research and treatment for the benefit of Service Members, Veterans, and the American public.

The ITP ASH 2024 grant initiative, offered by SANOFI, is designed to identify and fund projects that aim to close significant healthcare gaps related to the treatment and management of Immune Thrombocytopenia (ITP). ITP is a rare blood disorder characterized by a significantly reduced platelet count, leading to a heightened risk of bleeding and serious health complications such as thrombosis and hematologic malignancy. The chronic nature of ITP often results in a diminished quality of life for patients, manifesting in anxiety, fatigue, and depression due to ongoing concerns about bleeding risks and ineffective current therapies. SANOFI is particularly interested in supporting educational and therapeutic strategies that promise to enhance the clinical handling of ITP, focusing on innovative treatment methodologies and educational activities that can lead to improved patient outcomes. Proposals are invited for projects including, but not limited to, live symposiums at medical conferences, enduring materials for broader educational reach, and both accredited and non-accredited Independent Medical Education (IME) activities. A budget cap of $425,000 is set for the grant, with a strong preference for proposals that incorporate evidence-based approaches and demonstrate potential to address knowledge gaps among healthcare providers, thus improving treatment practices.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor announces an open competition for organizations interested in submitting applications for programs to bolster non-governmental organizations internal accessibility and inclusion policies and practices

The FY24 PCRP Idea Development Award is intended to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. The key components of this award mechanism are: Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative. Projects involving multidisciplinary and/or data science approaches are especially encouraged. Impact: Applications are required to address and provide a solution to one or more of the FY24 PCRP Overarching Challenges. The potential impact of the research, both short-term and long-term, in addressing the FY24 PCRP Overarching Challenge(s) should be clearly described. High-impact research will, if successful, significantly advance prostate cancer research and/or patient care. Preliminary Data: Due to this awards emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged, but not required. Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team. Regardless of whether preliminary data are included, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature.New Investigator category: The FY24 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category of this award mechanism is designed to allow applicant organizations to name PIs who are early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category will be assessed using different review criteria for personnel (refer to Section II.E.1.a., Peer Review) and are required to include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. The application must describe the potential of the collaboration(s) to be successful and how the collaboration(s) will augment the PIs expertise to better address the research question. In addition, applicants are strongly encouraged to provide a letter of collaboration from the collaborator(s) describing the collaborator(s) involvement in the proposed work. All applicants for the New Investigator category must meet specific eligibility criteria described in Section II.C, Eligibility Information.Multidisciplinary projects are encouraged, and multi-institutional projects are allowed. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Idea Development Award should not exceed $1.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $53.76M to fund approximately 28 Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

MDF is NICs Management Development for the Future series, a dynamic, agency exclusive, individual and organizational development experience, which primarily targets the middle management tier of a correctional organization. This established curriculum simultaneously engages all levels of agency leadership through internal action-based learning strategies at the individual, team and agency levels.This agency exclusive leadership development series is conducted over up to 12+ months and is provided to participants within selected partner agencies. The learning strategies used in this blended and hybrid delivery individual and organizational development series include three phases one in person 24 - hour (3 in-person days) and two fully virtual phases (seven, 3-hour virtual instructor led sessions with intersession activities between virtual sessions), each delivered approximately 4 - 5 months apart. Participants will prepare a dynamic leadership development plan, participate in individual developmental coaching, and during intercession periods between phases undertake action-based learning projects1 Campbell, Nancy M. Correctional Leadership Competencies for the 21stCentury: Executives and Senior-Level Leaders, July 2005, Retrieved from https://s3.amazonaws.com/static.nicic.gov/Library/020474.pdf2 Day, David V., John W. Fleenor, Leanna E. Atwater, Rachel E. Sturm, and Rob A. McKee. "Advances in Leader and Leadership Development: A Review of 25 Years of Research and Theory." The Leadership Quarterly 25, no. 1 (February 2014): 63-82.3 Zenger, Jack, and Joe Folkman. "Leadership Development 6.0: Connecting Leadership Development with Drivers of Business Results." Zenger Folkman, 2010. UT: Orem24AC07focused on the relevant issues in their agencies with the intention of applying skills and strategies learned in the program to build organizational capacity and manage organizational change between phases ones, two and three. The blended and hybrid MDF series simultaneously engages all levels of agency leadership through internal action-based learning strategies at the individual, team and agency levels.Pre-session activities prior to each phase include participants completing several online instruments, reading assignments and other required activities. This program is grounded in the evidence based Full Range Leadership Model developed by Bass, B. M., and Avolio, B. J. An on-line 360-degree feedback instrument assesses the participants behavior against the model.A proposal responsive to this solicitation should provide substantiated documentation of: 1) respondent organizational capacity and project management expertise and experience to manage multiple, overlapping projects simultaneously; 2) a minimum of 10 years of experience managing national and regional training events in corrections settings; 3) 10 years of substantiated experience setting up, hosting, producing and facilitating blended (virtual instructor led platforms) and face to face training series; 4) 10 years of substantiated experience facilitating blended and face to face leader training with correctional agencies (jails, prisons, community corrections); 5) proposed faculty with 10 years minimum experience, credentials and qualifications to administer, interpret and facilitate the Multifactor Leadership Questionnaire II, FIRO-B Interpretative Report for Organizations, Thomas-Kilman Conflict Mode Indicator and other instrumentation as needed based upon partner agency needs and their applications to corrections settings; 6) 10 years experience for proposed faculty to perform developmental leadership coaching; 7) 10 years experience facilitating experiential leadership training activities and tying them through content and leadership competencies to on the job leadership correctional applications; and 8) 10 years of experience working with executive and senior level leaders in correctional agencies on organizational development initiatives which advance agencies mission, vision and values.

The U.S. Department of State announces an open competition for organizations to submit applications to facilitate the launch of the Marine and Blue Economy Hackathon. Please follow all instructions in the "Marine and Blue Economy Hackathon NOFO Full Instructions" document under the Related Documents tab. Priority Region: Lagos, Nigeria Overview and Purpose Inadequate technological solutions and lack of coordination across Nigerias marine and blue economy-related sectors have led to untapped economic opportunities, unsustainable fishing practices, plastic pollution, and environmental damage. To implement the Partnership for Atlantic Cooperation Plan of Action and to bolster U.S.-Nigeria relations, a selected implementing partner, in consultation with the U.S. Mission Nigeria, will launch the Marine and Blue Economy Hackathon. This two- to three-day event will bring together approximately 60 working-level government officials, private sector experts, academics, entrepreneurs, and students to crowdsource innovative technical solutions to marine and blue economy-related problems. Defining Problem Statements, Crowdsourcing Solutions, and Measuring Results The selected implementing partner, in consultation with the U.S. Mission in Nigeria, will define three marine and blue economy-focused problem statements. Problem statements should reflect local needs and the priorities established by the Partnership for Atlantic Cooperation member countries including sustainable fisheries management, plastic pollution prevention, coastal community resilience, marine conservation, sustainable aquaculture management, ghost gear solutions, aquatic food technology advancement, ocean data and information gathering and analysis, and marine spatial planning implementation. During the hackathon, participants will: (a) translate multifaceted problems into succinct technical specifications and statements recognizable to software and technology designers; and (b) form teams to generate actionable and innovative technical solutions to the shared problem statement(s). At the end of the hackathon, a winner will be selected by a board of American and Nigerian judges for the most innovative and impactful solution developed, and a prize will be offered. After the hackathon, participants will then deploy the solutions they collaboratively design, leverage partnerships established with their counterparts across the sector, and closely coordinate with one another to ensure the solutions address the identified problems. Hackathon results can be measured by number and quality of targeted small-group sessions, the introduction of new tools and technologies, and creation of prototypes that address the problems hackathon participants tackle. In order to be considered, implementing partner applicants must demonstrate a clear commitment to inclusive participation. The selected implementing partner must reach out to potential participants from marginalized populations and communities, ensure balance among hackathon participants, and provide accessibility accommodations as needed. Participants and Audiences This two- to three-day event will bring together approximately 60 working-level government officials, private sector experts, academics, entrepreneurs, and students to crowdsource innovative technical solutions to marine and blue economy-related problems.

USAID Bureau for Global Healths (GH) Office of Population and Reproductive Health (PRH) will implement the Accelerating ChoiCe, Equity, and Sustainability for Services (ACCESS) award, which aims to improve SRH and related health outcomes among individuals across the life course. The award will reach underserved populations, with a particular focus on those who face the greatest inequities in FP/RH service delivery, including adolescents/youth and other marginalized groups, such as persons with disabilities, Indigenous Peoples, racial and ethnic minorities, persons living in extreme poverty, and LGBTQI+ personsmany of whom have intersecting identities.

The USAID funded Libya EVER Activity is a new five-year activity whose goal is to improve the effectiveness of key Libyan institutions and build the capacity of a diverse set of Libyan actors to advance the democratic political transition, including national and local elections, and support a stronger more inclusive democratic culture in Libya. The Libya EVER Activity (The Activity) has two main objectives: Objective 1: Strengthen Libyas election institutions and government stakeholders to carry out credible electoral and political processes at the local and national levels Objective 2: Empower the diversity of Libyas citizens and civil society to advance the democratic process in Libya.

The DOD Pancreatic Cancer, Translational Research Partnership Award is a funding opportunity designed to support collaborative research projects between clinicians and scientists, with the aim of accelerating the development and application of innovative ideas in pancreatic cancer treatment, prevention, diagnosis, and survivorship, and encouraging the reciprocal exchange of knowledge between basic and clinical science.

This funding opportunity provides financial support to state and local governments, public utilities, and agencies for the procurement and use of low-carbon products made from captured carbon emissions, promoting sustainable practices and environmental benefits.